Abstract: Provided are a donor vector having an exon-humanized gene in which only exon nucleotide sequences of a mouse gene are replaced with human exon nucleotide sequences, an ES cell in which a mouse endogenous gene is replaced with the donor vector, and a mouse crated by using the ES cell.
Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.
Type:
Grant
Filed:
July 31, 2014
Date of Patent:
September 8, 2020
Assignees:
TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
Abstract: The present invention provides embryonic stem cells obtained from an embryo of a mouse engineered to replace all or some of domains in the mouse MHC class I molecule H2-D with domains from the human MHC class I molecule HLA-A by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a mouse which is created with the use of these embryonic stem cells.
Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.
Type:
Application
Filed:
July 31, 2014
Publication date:
August 3, 2017
Applicants:
TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
Abstract: The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.
Type:
Grant
Filed:
February 12, 2009
Date of Patent:
November 11, 2014
Assignees:
Transgenic Inc., President, National Cancer Center
Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.
Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.
Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.